Assessing Clinical Outcomes in Alzheimer's Disease Agitation
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to
evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation
symptoms in subjects with agitation associated with Alzheimer's disease.